Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?

Area of Science:

• Oncology
• Pharmacology
• Genetics

Background:

• Standard-of-care EGFR tyrosine kinase inhibitors (TKIs) like erlotinib, gefitinib, and afatinib are used for EGFR mutation-positive non-small-cell lung cancer (NSCLC).
• Acquired resistance to first-generation TKIs, frequently mediated by the T790M mutation, limits long-term efficacy.
• Osimertinib has demonstrated clinical activity in T790M-positive NSCLC after progression on first-line TKIs and is approved for this indication.

Purpose of the Study:

• To review the efficacy and role of osimertinib in EGFR mutation-positive NSCLC.
• To discuss treatment sequencing strategies considering factors like resistance mutations, brain metastases, and tolerability.
• To highlight the evolving landscape of first-line treatment for EGFR-mutated NSCLC.

Main Methods:

• Review of clinical trial data and guidelines regarding EGFR TKIs in NSCLC.
• Analysis of resistance mechanisms, particularly the T790M mutation.
• Evaluation of osimertinib's efficacy in first-line and subsequent treatment settings.

Main Results:

• Osimertinib has shown significant clinical activity in T790M-positive NSCLC post-progression on first-generation TKIs.
• Recent data indicate improved efficacy of osimertinib compared to first-generation TKIs (erlotinib, gefitinib) in the first-line setting.
• Treatment decisions involve complex factors including subsequent therapy, brain metastases, and patient tolerability.

Conclusions:

• Osimertinib represents a significant advancement in managing EGFR mutation-positive NSCLC, both in the first-line setting and after progression.
• Optimizing long-term outcomes requires careful consideration of individual patient factors and treatment sequencing.
• Further research is needed to establish optimal treatment strategies and sequencing for EGFR-mutated NSCLC.